Recent Achievements in the Development of Radiolabeled Monoclonal Antibodies for Diagnosis, Therapy and Biologic Characterization of Human Tumors

Larson, Steven M.; Macapinlac, Homer A.; Scott, Andrew M.; Divgi, Chaitanya

doi:10.3109/02841869309096125

Cited by 13 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 Encouraging results using radiolabelled mAbs in clinical oncology trials have been reported, where their use has permitted diagnosis, patient stratification, and identification of the most appropriate treatment. 8 The rate of uptake from the blood to the biological target is approximately inversely proportional to the molecular mass of the APP; consequently, target accumulation of mAbs is relatively slow. 9 For this reason, longer-lived radioisotopes such as 89 Zr and 64 Cu have been conventionally used to radiolabel mAbs.…”

Section: Affinity Peptides and Proteins In Petmentioning

confidence: 99%

“…The method is recognised as a key development in the use of radiolabelled mAbs, and more recent achievements in recombinant techniques, permitting humanisation and chimerisation, have strengthened their clinical utility . Encouraging results using radiolabelled mAbs in clinical oncology trials have been reported, where their use has permitted diagnosis, patient stratification, and identification of the most appropriate treatment …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A review of approaches to ¹⁸F radiolabelling affinity peptides and proteins

Morris

Fairclough

Grigg³

et al. 2018

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Affinity peptide and protein- (APP) based radiotracers are an increasingly popular class of radiotracer in positron emission tomography (PET), which was once dominated by the use of small molecule radiotracers. Radiolabelled monoclonal antibodies (mAbs) are important examples of APPs, yet a preference for smaller APPs, which exhibit fast pharmacokinetics and permit rapid PET aided diagnosis, has become apparent. F exhibits favourable physical characteristics for APP radiolabelling and has been described as an ideal PET radionuclide. Notwithstanding, F radiolabelling of APP is challenging, and this is echoed in the literature where a number of diverse approaches have been adopted. This review seeks to assess and compare the approaches taken to F APP radiolabelling with the intention of highlighting trends within this expanding field. Generic themes have emerged in the literature, namely the use of mild radiolabelling conditions, a preference of site-specific methodologies with an impetus for short, automated procedures which produce high-yielding [ F]APPs.

show abstract